Anand-Ivell Ravinder, Yang Xinyuan, Braun Ruediger, Ungefroren Hendrik, Ivell Richard
School of Biosciences, University of Nottingham, Sutton Bonington, United Kingdom.
Department of Surgery, University Medical Center Schleswig-Holstein (UKSH), Lübeck, Germany.
Front Endocrinol (Lausanne). 2025 Aug 27;16:1625906. doi: 10.3389/fendo.2025.1625906. eCollection 2025.
Pancreatic ductal carcinoma (PDAC) is a rapidly growing cancer with a very poor prognosis. It is, therefore, important to develop novel, specific biomarkers to identify such cancers as early as possible. In a recent article published in , Yeom and colleagues postulated that circulating insulin-like peptide 3 (INSL3) might serve as such a biomarker. Experiments were first conducted in to show that the Dilp8/Lgr3 system regulated the fly equivalent of cachexia. This was then translated to humans to imply the involvement of the INSL3/RXFP2 system in PDAC-associated cachexia and that circulating INSL3 might serve as an early PDAC biomarker. We have now analyzed blood and tumor tissue from PDAC patients using a well-validated and recognized INSL3 immunoassay and specific antihuman INSL3 antibodies, and find no evidence to support these claims. We consider that this is largely due to Yeom and colleagues using a poorly validated immunoassay and antibodies for INSL3. Unfortunately, therefore, this peptide is not suitable for consideration as a PDAC biomarker.
胰腺导管腺癌（PDAC）是一种生长迅速且预后极差的癌症。因此，开发新的、特异性的生物标志物以尽早识别此类癌症非常重要。在最近发表于某期刊的一篇文章中，Yeom及其同事推测循环胰岛素样肽3（INSL3）可能充当这样一种生物标志物。实验首先在果蝇中进行，以表明Dilp8/Lgr3系统调节果蝇的恶病质。随后将其应用于人类，以暗示INSL3/RXFP2系统参与PDAC相关恶病质，并且循环INSL3可能作为早期PDAC生物标志物。我们现在使用经过充分验证和认可的INSL3免疫测定法及特异性抗人INSL3抗体分析了PDAC患者的血液和肿瘤组织，未发现支持这些说法的证据。我们认为这主要是因为Yeom及其同事使用了未经充分验证的INSL3免疫测定法和抗体。因此，不幸的是，这种肽不适合作为PDAC生物标志物来考虑。
